AZD4573

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed or Refractory Haematological Malignancies Including

Conditions

Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Richter's Syndrome, B-cell Non-Hodgkin Lymphoma, T-cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Multiple Myeloma

Trial Timeline

Oct 24, 2017 โ†’ Sep 30, 2021

About AZD4573

AZD4573 is a phase 1 stage product being developed by AstraZeneca for Relapsed or Refractory Haematological Malignancies Including. The current trial status is completed. This product is registered under clinical trial identifier NCT03263637. Target conditions include Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT05140382Phase 2Completed
NCT03263637Phase 1Completed

Competing Products

20 competing products in Relapsed or Refractory Haematological Malignancies Including

See all competitors